Table 1 Baseline.
characteristics of cyclophosphamide (CYC) and enteric-coated mycophenolic sodium (EC-MPS) groups
| Patients characteristic | CYC (n=32) | EC-MPS (n=27) |
|---|---|---|
| Female, n (%) | 32 (100) | 26 (96.3) |
| Age at enrolment (years; mean±SD) | 30.2±7.0 | 35.4±12.9 |
| Median time (min–max) of lupus nephritis (months) | 46.5 (4.0–158.0) | 60.5 (3.0–240.0) |
| Systolic blood pressure (mm Hg; mean±SD) | 132±17 | 136±19 |
| Diastolic blood pressure (mm Hg; mean±SD) | 85±16 | 87±14 |
| Renal pathology, n (%) | ||
| ISN/RPS class III | 10% | 4% |
| ISN/RPS class IV | 90% | 96% |
| Relapse/resistant cases (%) | 34.4/65.6 | 37.0/63.0 |
| Serum creatinine (mg/dL; mean±SD) | 0.90±0.42 | 0.99±0.40 |
| eGFR by chronic kidney disease epidemiology (mL/min/1.73 m2; mean±SD) | 96.5±30.8 | 84.7±29.9 |
| Range of eGFR (mL/min/1.73 m2; n (%)) | ||
| ≥90 mL/min/1.73 m2 | 21 (65.6) | 15 (55.6) |
| 60–89 mL/min/1.73 m2 | 5 (15.6) | 4 (14.8) |
| 45–59 mL/min/1.73 m2 | 3 (9.4) | 4 (14.8) |
| 30–44 mL/min/1.73 m2 | 2 (6.3) | 3 (11.1) |
| 25–30 mL/min/1.73 m2 | 1 (3.1) | 1 (3.7) |
| Haemoglobin (g/dL; mean±SD) | 10.8±1.9 | 10.7±1.5 |
| Haematocrit (%; mean±SD) | 33.1±5.4 | 32.6±4.5 |
| Serum albumin (g/dL; mean±SD) | 2.88±0.72 | 2.68±0.69 |
| Serum complement (mg/dL, mean±SD) | ||
| C3 concentration | 72.1±35.2 | 71.8±32.6 |
| C4 concentration | 17±12.7 | 16.4±11.4 |
| UPCR (mean±SD) | 7.5±5.3 | 9.0±6.1 |
| Nephrotic-range proteinuria (≥3.5 g/day), n (%) | 22 (68.8) | 24 (88.9) |
| Urine red blood cell (cells/hpf; mean±SD) | 27.8±43.8 | 34.4±70.2 |
| Urine white cell (cells/hpf; mean±SD) | 14.1±55.8 | 10.8±29.1 |
eGFR, estimated glomerular filtration rate; hpf, high-power field; ISN/RPS, International Society of Nephrology/Renal Pathology Society; UPCR, urine protein creatinine ratio (mg/mg).